Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Blesilda Ellis

Pulmonary Disease New Orleans, LA Medical Doctor

NPI 1427089234 CMS profile 64817

1415 Tulane Ave Fl 7, New Orleans, LA 70112

Open in the dashboard

General payments

$7,444

424 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Blesilda Ellis of New Orleans, LA is reported in the CMS Open Payments database as having received $7,444 across 424 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $138 2
2024 General $123 1
2023 General $167 3
2022 General $2,203 134
2021 General $1,684 99
2020 General $1,140 70
2019 General $1,990 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Blesilda Ellis
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Blesilda Ellis were reported at $138. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Blesilda Ellis Pulmonary Disease median Middle half National median
2019 $1,990 $377 $109–$1,340 $163
2020 $1,140 $230 $56–$907 $114
2021 $1,684 $269 $68–$1,072 $132
2022 $2,203 $390 $100–$1,457 $149
2023 $167 $419 $114–$1,659 $160
2024 $123 $476 $123–$1,818 $164
2025 $138 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,523 120 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $1,254 60 payments
  3. AstraZeneca Pharmaceuticals LP $772 49 payments
  4. Actelion Pharmaceuticals US, Inc. $723 25 payments
  5. Insmed, Inc. $485 12 payments
  6. Grifols USA, LLC $476 28 payments
  7. United Therapeutics Corporation $358 22 payments
  8. Genentech USA, Inc. $294 21 payments
  9. Electromed, Inc. $253 24 payments
  10. Regeneron Healthcare Solutions, Inc. $227 11 payments
  11. Other $1,082 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,215 419 payments
  2. Education $229 5 payments
Products named General payments · program years 2019–2025
  1. OFEV $1,476 75 payments
  2. TRELEGY ELLIPTA $797 65 payments
  3. UPTRAVI $723 25 payments
  4. OPSUMIT $594 18 payments
  5. Arikayce $485 12 payments
  6. Prolastin-C Liquid $476 28 payments
  7. NUCALA Immunology $309 21 payments
  8. FASENRA $261 14 payments
  9. NUCALA Respiratory $258 17 payments
  10. Xolair $251 18 payments
  11. Other $3,383 211 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$48,863

Medicare's payments for the services billed

Medicare patients

96

Average age 72

Services billed

383

43 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 56%
Diabetes 55%
Heart failure 54%
Ischemic heart disease 48%
Atrial fibrillation 47%
Arthritis 45%
COPD 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Rezzayo
  • Melinta Therapeutics, Inc. $123
$123 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

424 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record